Literature DB >> 25602110

Vemurafenib and cobimetinib in BRAF-mutated melanoma.

Ahmadur Rahman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25602110     DOI： 10.1016/s1470-2045(14)71023-x

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

Review 1.  Recent advances in the treatment of melanoma with BRAF and MEK inhibitors.

Authors:  Eva Muñoz-Couselo; Jesús Soberino García; José Manuel Pérez-García; Vanesa Ortega Cebrián; Javier Cortés Castán
Journal:  Ann Transl Med       Date:  2015-09

Review 2.  Cobimetinib: First Global Approval.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

Review 3.  Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.

Authors:  Chune Yu; Xiaowei Liu; Jiqiao Yang; Min Zhang; Hongyu Jin; Xuelei Ma; Hubing Shi
Journal:  Front Immunol       Date:  2019-05-07       Impact factor: 7.561

4.  Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma.

Authors:  Alexandre Harlé; Julia Salleron; Claire Franczak; Cindy Dubois; Pierre Filhine-Tressarieu; Agnès Leroux; Jean-Louis Merlin
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.